X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Lead Product(s): Raltegravir Potassium
Therapeutic Area: Infections and Infectious Diseases Product Name: Raltegravir-Generic
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Midas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
